Clinical Trials Logo

Transformed Non-Hodgkin Lymphoma clinical trials

View clinical trials related to Transformed Non-Hodgkin Lymphoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03749018 Active, not recruiting - Clinical trials for Diffuse Large B-Cell Lymphoma

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Start date: January 2, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well nivolumab works with the DA-REPOCH chemotherapy regimen in treating patients with aggressive B-cell non-Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body?s immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as dose-adjusted rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (DA-REPOCH), work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab with DA-REPOCH may work better in treating patients with aggressive B-cell non-Hodgkin lymphoma.